Olympus Biotech Announces Reduced Sale Price For New Hampshire Biopharmaceutical Manufacturing Facility

        Olympus Biotech Announces Reduced Sale Price For New Hampshire
                   Biopharmaceutical Manufacturing Facility

Olympus Biotech initiating aggressive transaction process aided by
pharmaceutical and biotechnology consultants, PharmaBioSource Realty LLC

PR Newswire

LEBANON, N.H., March 3, 2014

LEBANON, N.H., March 3, 2014 /PRNewswire/ --Olympus Biotech today announced
the initiation of an aggressive transaction process to find a buyer of its
West Lebanon, NH manufacturing facility over the next 90 days. In recent
months, the Company has received interest from buyers and contract
manufacturing organization (CMO) partners, but no deal has been consummated

"We feel that this is an opportunity for a biotech or pharmaceutical company
to acquire a world class site at a small fraction of the replacement cost.
The value for the manufacturing plant and related assets has been reduced to a
nominal value," said Peter Gariepy, VP of Operations and Plant Manager. "We
have written down the facility and are pursuing an aggressive sales process to
showcase this attractive offer to the Life Sciences industry."

The facility has an extensive history of manufacturing mammalian cell based
products for the biopharmaceutical industry and has a successful track record
in producing both clinical and commercial bulk product. The facility is cGMP
certified by several health authorities and has an excellent inspection
record. Nearly 130 facility personnel have expertise in manufacturing and
facility operations, engineering, development, quality assurance, quality
control, validation, and operational excellence.

As an 180,000 sq. ft. manufacturing plant with expansion space and land for
additional needs, the plant houses two mammalian cell culture suites with
fixed and single use platforms as well as an area dedicated to process
development activity. Each suite offers independent cell culture equipment
trains and dedicated areas for product recovery and purification. Downstream
areas can support an array of column chromatography and filtration processes
including affinity, ion exchange, hydrophobic interaction, gel filtration,
ultrafiltration, and diafiltration. Clinical aseptic fill capacity was
recently introduced at the site using barrier isolator technology. Robust
utility systems support 24/7 operations across all manufacturing and support

To see a video tour of the facility please visit:

For technical information, please contact Sean McKee at PharmaBioSource at
(484) 686-0123.

About Olympus Biotech Corporation
Olympus Biotech was established in December, 2010 as a wholly owned company of
Olympus Corporation of the Americas. The vision of Olympus Biotech is to
improve the patient Quality of Life by developing and distributing
Regenerative Medicines that stimulate the intrinsic healing capacity in the
living body by the technological development of growth factors and

About Olympus
Based in Tokyo, Olympus is a global precision technology leader, designing and
delivering innovative solutions in its core business areas:

  oMedical and Surgical Products: Gastrointestinal endoscopy, minimally
    invasive surgical products, and accessories
  oLife Science Imaging Systems: Advanced research, clinical/educational
    microscopes, and research/educational digital imaging systems
  oIndustrial Measurement and Imaging Instruments: Industrial research,
    engineering, test, inspection and measuring instruments
  oCameras and Audio Products: Digital cameras and voice recorders

Through this technology, Olympus focuses on enhancing people's lives every day
and helping people enjoy the continuum of life.

Contact: Michele Mendelson
          kwittken + company
          (646) 747-7163



SOURCE Olympus Biotech
Press spacebar to pause and continue. Press esc to stop.